1Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-sup-pression of homologous genes in trans [ J]. Plant Celll, 1990,2 (4) :279-289.
2Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs [J]. Cell, 2006,126(2) :231-235.
3Whitehead KA, Langer R, Anderson DG. Knocking down barri- ers: advances in siRNA delivery [ J ]. Nat Rev Drug Discov, 2009,8(8) :129-138.
4Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanop- articles[J]. Nature, 2010,464(7291) :1067-1071.
5Peer D, Park E J, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target [J]. Science, 2008,319(5863) : 627-630.
6Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics[J]. Silence, 2010,1 (8) :1-13.
7Braasch DA, Jensen S, Liu Y, et al. RNA interference in mamma- lian cells by chemically-modified RNA [ J ]. Biochemistry, 2003, 42 ( 26 ) : 7967 -7975.
8Chiu Y, Rana T. siRNA function in RNAi: a chemical modifica- tion analysis[J]. RNA, 2003,9(9) :1034-1048.
9Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs [ J ]. RNA, 2004,10 ( 5 ) : 766 -771.
10Cheng K, Ye Z, Guntaka RV, et al. Enhanced hepatic uptake and bioactivity of type al (I) collagen gene promoter-specific triplex- forming oligonuclcotides after conjugation with cholesterol [ J ]. J Pharmaeol Exp Ther, 2006,317(2) :797-805.
